7-5989845-C-T
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_000535.7(PMS2):c.1099G>A(p.Val367Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000186 in 1,612,874 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000535.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152156Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000438 AC: 11AN: 251260Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135776
GnomAD4 exome AF: 0.0000199 AC: 29AN: 1460718Hom.: 0 Cov.: 29 AF XY: 0.0000193 AC XY: 14AN XY: 726678
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152156Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74332
ClinVar
Submissions by phenotype
not provided Uncertain:2
This variant is denoted PMS2 c.1099G>A at the cDNA level, p.Val367Ile (V367I) at the protein level, and results in the change of a Valine to an Isoleucine (GTC>ATC). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. PMS2 Val367Ile was observed at an allele frequency of 0.03% (5/16510) in individuals of South Asian ancestry in large population cohorts (NHLBI Exome Sequencing Project, The 1000 Genomes Consortium 2015, Lek 2016). Since Valine and Isoleucine share similar properties, this is considered a conservative amino acid substitution. PMS2 Val367Ile occurs at a position where amino acids with properties similar to Valine are tolerated across species and is not located in a known functional domain. In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether PMS2 Val367Ile is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. -
- -
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
The p.V367I variant (also known as c.1099G>A), located in coding exon 10 of the PMS2 gene, results from a G to A substitution at nucleotide position 1099. The valine at codon 367 is replaced by isoleucine, an amino acid with highly similar properties. This variant was reported in an Asian patient undergoing multigene panel testing; this individual was diagnosed with breast cancer at age 49, had no reported family history of cancer, and also carried another alteration in the PMS2 gene (Chan GHJ et al. Oncotarget. 2018 Jul;9:30649-30660). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
- -
not specified Uncertain:1
Variant summary: PMS2 c.1099G>A (p.Val367Ile) results in a conservative amino acid change in the encoded protein sequence. Three of four in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.4e-05 in 251260 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in PMS2 causing Lynch Syndrome (4.4e-05 vs 0.00011), allowing no conclusion about variant significance. c.1099G>A has been reported in the literature as a VUS in settings of multigene panel testing for individuals affected with multiple primary cancers (example, Chan_2018). These report(s) do not provide unequivocal conclusions about association of the variant with Lynch Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 30093976). Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 (LB, n=1; VUS, n=5). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Lynch syndrome 4 Uncertain:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
Lynch syndrome Benign:1
- -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at